ConductScience.org, home

Paper54800

Clofibrate-induced muscle damage in patients with chronic renal failure.

Pierides AM and 2 others. Lancet, 1975. Cited by 153 papers, by iCite.

Cite this record

ConductScience Library. Clofibrate-induced muscle damage in patients with chronic renal failure. Papers, record 54800. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/54800

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clofibrate-induced muscle damage in patients with chronic renal failure.
PubMed
Journal
Lancet
PubMed
Year
1975
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
153
iCite
Relative citation ratio, by iCite
8.32
iCite
Revised in PubMed
2019-06-10
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pierides AMA M
2Alvarez-Ude FF
3Kerr DND N

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ClofibrateMajor topic
Kidney Failure, ChronicMajor topic
Muscular DiseasesMajor topic
Adult
Alanine Transaminase
Aspartate Aminotransferases
Butyrates
Cholesterol
Creatine Kinase
Creatinine
Female
Humans
Hyperlipidemias
L-Lactate Dehydrogenase
Male
Middle Aged
Triglycerides
Urea

Source PubMed

Download CSV of topics

Cited by29

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 153 citations.

PMIDTitleJournalYearIn PapersSource
35281975The Effects of Clofibrate on Neonatal Jaundice: A Systematic Review.Int J Prev Med2022https://conductscience.org/library/papers/35281975PubMed
27517384Clofibrate in insulin-dependent diabetes.Ir J Med Sci1979https://conductscience.org/library/papers/27517384PubMed
20006793Disorders of lipid metabolism and chronic kidney disease in the elderly.Semin Nephrol2009https://conductscience.org/library/papers/20006793PubMed
10217531Modulation of the gating of CIC-1 by S-(-) 2-(4-chlorophenoxy) propionic acid.Br J Pharmacol1999https://conductscience.org/library/papers/10217531PubMed
8148686Myxoedema revealed by simvastatin induced myopathy.BMJ1994https://conductscience.org/library/papers/8148686PubMed
7437867Acute renal failure and interstitial nephritis after clofibrate treatment.Br Med J1980https://conductscience.org/library/papers/7437867PubMed
7318880Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.Eur J Clin Pharmacol1981https://conductscience.org/library/papers/7318880PubMed
7289450[Rhabdomyolysis with acute renal failure due to bezafibrate].Klin Wochenschr1981https://conductscience.org/library/papers/7289450PubMed
7132229[Fat and renal failure--therapeutic aspects].Klin Wochenschr1982https://conductscience.org/library/papers/7132229PubMed
7037261Drug metabolites in renal failure: pharmacokinetic and clinical implications.Clin Pharmacokinet1981https://conductscience.org/library/papers/7037261PubMed
6759093Pharmacologically active metabolites of drugs and other foreign compounds. Clinical, pharmacological, therapeutic and toxicological considerations.Drugs1982https://conductscience.org/library/papers/6759093PubMed
6727274[Bezafibrate-induced myolysis and myoglobinuria in patients with impaired renal function].Klin Wochenschr1984https://conductscience.org/library/papers/6727274PubMed
6705423Alteration of drug-protein binding in renal disease.Clin Pharmacokinet1984https://conductscience.org/library/papers/6705423PubMed
6386024The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia.Br J Clin Pharmacol1984https://conductscience.org/library/papers/6386024PubMed
6128217Adverse effects of drugs on muscle.Drugs1982https://conductscience.org/library/papers/6128217PubMed
4072624Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report.Acta Neuropathol1985https://conductscience.org/library/papers/4072624PubMed
3784441Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects.Klin Wochenschr1986https://conductscience.org/library/papers/3784441PubMed
3547004Adverse effects of hypolipidaemic drugs.Med Toxicol1987https://conductscience.org/library/papers/3547004PubMed
2203581Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).Clin Pharmacokinet1990https://conductscience.org/library/papers/2203581PubMed
1921228[Pathophysiology and therapy of lipid metabolism disorders in kidney diseases].Klin Wochenschr1991https://conductscience.org/library/papers/1921228PubMed

See all 29 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/54800

GET https://conductscience.org/api/papers/v1/54800/cited_by?page=2